Cholesteryl Ester Transfer Protein (CETP) genotype and reduced CETP levels associated with decreased prevalence of hypertension

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

OBJECTIVES: To clarify whether reduced cholesteryl ester transfer protein (CETP) activity carries inherent blood pressure risks and to infer whether the increased blood pressure and elevated mortality associated with torcetrapib are idiosyncratic or characteristic of this class of drugs. PATIENTS AND METHODS: We examined the associations among CETP genotype, phenotype, and blood pressure in a cohort of 521 older adults (who have complete data for the variables required in our primary analysis) enrolled between November 1, 1998, and June 30, 2003, in our ongoing studies of genes associated with longevity, including a cohort with a high prevalence of a genotype coding for a reduced activity variant of CETP and low levels of CETP. RESULTS: The prevalence of hypertension was actually lower among homozygotes for the variant CETP (48% vs 60% among those with wild-type and 65% among heterozygotes; P=.03). Low levels of CETP were associated with reduced prevalence of hypertension (65% in highest tertile, 59% in middle tertile, and 55% in lowest tertile; P=.04) and lower systolic blood pressure (140.8, 138.1, 136.2 mm Hg, respectively; P=.03). CONCLUSION: Reduced levels of CETP are associated with lower, not higher, blood pressure. The adverse results with torcetrapib, if mediated through blood pressure, are likely to represent effects of this specific drug, rather than a result of lower CETP levels.

Original languageEnglish (US)
Pages (from-to)522-526
Number of pages5
JournalMayo Clinic Proceedings
Volume85
Issue number6
DOIs
StatePublished - 2010

Fingerprint

Cholesterol Ester Transfer Proteins
Genotype
Hypertension
Blood Pressure
Homozygote
Heterozygote
Pharmaceutical Preparations
Phenotype
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{6e03f1a998044a728ed1085b50efdb73,
title = "Cholesteryl Ester Transfer Protein (CETP) genotype and reduced CETP levels associated with decreased prevalence of hypertension",
abstract = "OBJECTIVES: To clarify whether reduced cholesteryl ester transfer protein (CETP) activity carries inherent blood pressure risks and to infer whether the increased blood pressure and elevated mortality associated with torcetrapib are idiosyncratic or characteristic of this class of drugs. PATIENTS AND METHODS: We examined the associations among CETP genotype, phenotype, and blood pressure in a cohort of 521 older adults (who have complete data for the variables required in our primary analysis) enrolled between November 1, 1998, and June 30, 2003, in our ongoing studies of genes associated with longevity, including a cohort with a high prevalence of a genotype coding for a reduced activity variant of CETP and low levels of CETP. RESULTS: The prevalence of hypertension was actually lower among homozygotes for the variant CETP (48{\%} vs 60{\%} among those with wild-type and 65{\%} among heterozygotes; P=.03). Low levels of CETP were associated with reduced prevalence of hypertension (65{\%} in highest tertile, 59{\%} in middle tertile, and 55{\%} in lowest tertile; P=.04) and lower systolic blood pressure (140.8, 138.1, 136.2 mm Hg, respectively; P=.03). CONCLUSION: Reduced levels of CETP are associated with lower, not higher, blood pressure. The adverse results with torcetrapib, if mediated through blood pressure, are likely to represent effects of this specific drug, rather than a result of lower CETP levels.",
author = "Schechter, {Clyde B.} and Nir Barzilai and Crandall, {Jill P.} and Gil Atzmon",
year = "2010",
doi = "10.4065/mcp.2009.0594",
language = "English (US)",
volume = "85",
pages = "522--526",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Cholesteryl Ester Transfer Protein (CETP) genotype and reduced CETP levels associated with decreased prevalence of hypertension

AU - Schechter, Clyde B.

AU - Barzilai, Nir

AU - Crandall, Jill P.

AU - Atzmon, Gil

PY - 2010

Y1 - 2010

N2 - OBJECTIVES: To clarify whether reduced cholesteryl ester transfer protein (CETP) activity carries inherent blood pressure risks and to infer whether the increased blood pressure and elevated mortality associated with torcetrapib are idiosyncratic or characteristic of this class of drugs. PATIENTS AND METHODS: We examined the associations among CETP genotype, phenotype, and blood pressure in a cohort of 521 older adults (who have complete data for the variables required in our primary analysis) enrolled between November 1, 1998, and June 30, 2003, in our ongoing studies of genes associated with longevity, including a cohort with a high prevalence of a genotype coding for a reduced activity variant of CETP and low levels of CETP. RESULTS: The prevalence of hypertension was actually lower among homozygotes for the variant CETP (48% vs 60% among those with wild-type and 65% among heterozygotes; P=.03). Low levels of CETP were associated with reduced prevalence of hypertension (65% in highest tertile, 59% in middle tertile, and 55% in lowest tertile; P=.04) and lower systolic blood pressure (140.8, 138.1, 136.2 mm Hg, respectively; P=.03). CONCLUSION: Reduced levels of CETP are associated with lower, not higher, blood pressure. The adverse results with torcetrapib, if mediated through blood pressure, are likely to represent effects of this specific drug, rather than a result of lower CETP levels.

AB - OBJECTIVES: To clarify whether reduced cholesteryl ester transfer protein (CETP) activity carries inherent blood pressure risks and to infer whether the increased blood pressure and elevated mortality associated with torcetrapib are idiosyncratic or characteristic of this class of drugs. PATIENTS AND METHODS: We examined the associations among CETP genotype, phenotype, and blood pressure in a cohort of 521 older adults (who have complete data for the variables required in our primary analysis) enrolled between November 1, 1998, and June 30, 2003, in our ongoing studies of genes associated with longevity, including a cohort with a high prevalence of a genotype coding for a reduced activity variant of CETP and low levels of CETP. RESULTS: The prevalence of hypertension was actually lower among homozygotes for the variant CETP (48% vs 60% among those with wild-type and 65% among heterozygotes; P=.03). Low levels of CETP were associated with reduced prevalence of hypertension (65% in highest tertile, 59% in middle tertile, and 55% in lowest tertile; P=.04) and lower systolic blood pressure (140.8, 138.1, 136.2 mm Hg, respectively; P=.03). CONCLUSION: Reduced levels of CETP are associated with lower, not higher, blood pressure. The adverse results with torcetrapib, if mediated through blood pressure, are likely to represent effects of this specific drug, rather than a result of lower CETP levels.

UR - http://www.scopus.com/inward/record.url?scp=77952896348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952896348&partnerID=8YFLogxK

U2 - 10.4065/mcp.2009.0594

DO - 10.4065/mcp.2009.0594

M3 - Article

C2 - 20511482

AN - SCOPUS:77952896348

VL - 85

SP - 522

EP - 526

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -